123
Participants
Start Date
December 21, 2020
Primary Completion Date
August 31, 2023
Study Completion Date
June 30, 2026
Tiragolumab
Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Atezolizumab
Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Carboplatin
Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
Etoposide
Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
Tiragolumab Matching Placebo
Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Beijing Cancer Hospital, Beijing
Beijing Chest Hospital, Beijing
the First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Chest Hospital, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
the First Affiliated Hospital of Bengbu Medical College, Bengbu
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The 1st Affiliated Hospital of Nanchang Unversity, Nanchang
Fujian Provincial Cancer Hospital, Fuzhou
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Henan Cancer Hospital, Zhengzhou
Cancer Center of Guangzhou Medical University, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
Hoffmann-La Roche
INDUSTRY